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Background:
Triple-negative breast cancer (TNBC) is highly aggressive combining with fast
metastatic behavior, which has the lowest survival rate among all breast cancer types.
Doxorubicin (DOX) is one of the most used in breast cancer patients after surgery.
However, severe cardiotoxicity and poor tumor penetration depth, for DOX relative
treatment to hinder its clinical practice. Furthermore, DOX relative treatment cannot
restrain the metastasis of TNBC and inhibit tumor recurrences. Therefore, a rational,
complementing chemotherapeutic agent would reduce drug dosage to overcome
cardiotoxicity, improve tumor perfusion to maintain intratumoral drug delivery, and
prevent the tumor metastasis is necessary.
Our solution:
In this work, our groups have resolved these important problems and report developed
a novel nanosystem by a designed assembly method to overcome tumor penetration
depth, tumor metastasis, and cardiotoxicity. We predicted that the large (~36 nm) self-
assembled temperature sensitive nanoclusters (TSNCs) could possess good blood
persistence and preferential tumor accumulation due to their EPR effect. The TSNCs
could be disassembled into ultrasmall nanodots (~ 6 nm) under the near-infrared (NIR)
laser irradiation, accelerating the deep penetration in the intratumoral environment.
Significance:
There are multiple major advances in our work and include:
the nanosystem can significantly improve the drug penetration depth under NIR laser
exposure due to their changeable particle size;
the nanosystem can eradicate breast Cancer Stem Cells and then could inhibit lung
and liver metastasis of TNBC;
Non-cardiotoxicity was evaluated by echocardiography image after treatment;
The treatment can be guided by PET and photoacoustic dual-imaging.
Nanoscale device such as this may overcome one of the major concerns associated
with the clinical translation of functional nanoparticles, which is cardiotoxic effect of
DOX. The nanoparticle platform has broad preclinical and clinical implications.
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Abstract: Triple-negative breast cancer (TNBC) is a kind of aggressive malignancy with fast
metastatic behavior. Here, we developed a nanosystem loaded with a near-infrared
(NIR) agent to achieve chemo-photothermal combination therapy for inhibiting tumor
growth and metastasis in TNBC. The NIR agent of ultrasmall sized copper sulfide
nanodots with strong NIR light-absorbing capability, is entrapped into the doxorubicin-
contained temperature sensitive polymer-based nanosystem by a self-assembled
method. The temperature sensitive multifunctional nanosystem (TSNCs) can
significantly enhance the drug penetration depth and significantly kill the cancer cells
under the near-infrared laser irradiation. Importantly, we found the tumor penetrating
nanosystem combined with NIR laser irradiation can prevent lung and liver metastasis
via extermination of the cancer stem cells. The in vivo characteristics, evaluated by
photoacoustic imaging, positron emission tomography imaging, pharmacokinetics, and
biodistribution, confirmed their feasibility for tumor treatment owing to their long blood
circulation time and high tumor uptake. Thanks to the high tumor uptake and highly
potent antitumor efficacy, the doxorubicin-induced cardiotoxicity can be avoided when
the TSNCs was used. Taken together, we believed that the nanosystem has excellent
potential for clinical translation.
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Triple-negative breast cancer (TNBC) is a kind of aggressive malignancy with fast metastatic 
behavior. Here, we developed a nanosystem loaded with a near- infrared (NIR) agent to 
achieve chemo-photothermal combination therapy for inhibiting tumor growth and metastasis 
in TNBC. The NIR agent of ultrasmall sized copper sulfide nanodots with strong NIR light-
absorbing capability, is entrapped into the doxorubicin-contained temperature sensitive 
polymer-based nanosystem by a self-assembled method. The temperature sensitive 
multifunctional nanosystem (TSNCs) can significantly enhance the drug penetration depth 
and significantly kill the cancer cells under the near- infrared laser irradiation. Importantly, it 
is plausible that the tumor penetrating nanosystem combined with NIR laser irradiation can 
prevent lung and liver metastasis via extermination of the cancer stem cells. The in vivo 
characteristics, evaluated by photoacoustic imaging, positron emission tomography imaging, 
pharmacokinetics, and biodistribution, confirmed their feasibility for tumor treatment owing 
to their long blood circulation time and high tumor uptake. Thanks to the high tumor uptake 
and highly potent antitumor efficacy, the doxorubicin- induced cardiotoxicity can be avoided 
when the TSNCs was used. Taken together, we believed that the nanosystem has excellent 
















































































Breast cancer ranks second among the most prevalent ma lignancies in the world. [1,2] 
Triple-negative breast cancer (TNBC) consists of 10-20% of breast cancer cases and is 
considered as the most aggressive subtype.[3,4] Due to the absence or low expression of 
progesterone, Her2/Neu, and estrogen receptors, TNBC is typically heterogeneous and 
aggressive. The prognosis of TNBC is bad and treatment options are limited.[5-7] 
Consistent with its aggressive nature, within five years after diagnosis, TNBC is often 
associated with high rates of lung and liver metastasis, despite adjuvant chemotherapy. [8-
10] Therefore, it is highly demanded to develop efficient therapeutic platforms for TNBC. 
Commonly, chemotherapy is preferential treatment in breast cancer patients after surgery, 
while doxorubicin (DOX) is one of the most used chemotherapeutic drugs.[11,12] 
However, DOX mediated chemotherapy was restricted by several major issues, such as 
severe cardiotoxicity and poor tumor penetration depth, in clinical practice.[13-16] 
Furthermore, DOX relative treatment cannot restrain the metastasis of TNBC and inhibit  
tumor recurrences.[17,18] Therefore, a rational, complementing chemotherapeutic agent 
would reduce drug dosage to overcome cardiotoxic ity, improve tumor perfusion to 
maintain intratumoral drug delivery, and prevent the tumor metastasis is necessary.  
Nanoparticle-based drug delivery system has emerged as an advanced technology for 
spatiotemporally controlled codelivery of different anticancer drugs to the tumor sites 
through the enhanced permeability and retention (EPR) effect.[19-21] However, poor tumor 
deep penetration of nanotherapeutics, owing to the non-uniformly leaky vasculature and a 
dense interstitial structure of tumor, lead to suboptima l therapeutic effect and severely 
hinder the clinic translation of this developments.[22] Ultrasmall nanoparticles have the 
ability to distribute more homogeneity within tumors.[23] It has been shown that 7 nm 





































































than the large-sized nanoparticles in several tested breast cancer mouse models.[24] 
Unfortunately, the ultrasmall sized nanoparticles (less than 7 nm) limit their efficacy for 
tumor targeting due to their rapid clearance characteristics.[25-27] On the contrary, larger 
nanoparticles with slower migration rate are more advantageous for high accumulation 
and retention in the tumor, but they are inherently unfavorable for reaching the deep 
region of the tumor due to their giant pervasion obstruction.[28] Therefore, for high 
accumulation and deep tumor penetration, an ideal nanocarrier should be able to change 
to small size from its initial large size that favors longer circulation and selective 
extravasation.[24,29-36] Previous studies have shown that nanoparticles in the range of 30-
50 nm exhibit great tumor uptake, excellent penetration capability for poorly permeable 
tumors to achieve the better antitumor effect.[37] 
Here, we developed a novel nanosystem by a designed assembly method to overcome 
tumor penetration depth, tumor metastasis, and cardiotoxicity. We predicted that the large 
(~36 nm) self-assembled temperature sensitive nanoclusters (TSNCs) could possess good 
blood persistence and preferential tumor accumulation due to their  EPR effect. The 
TSNCs could be disassembled into ultrasmall nanodots  (~ 6 nm) under the near- infrared 
(NIR) laser irradiation, accelerating the deep penetration in the intratumoral environment. 
The pharmacokinetics, biodistribution, and tumor accumulation characteristics of the 
TSNCs were investigated by radio- labeling, and photoacoustic imaging. The laser-
induced tumor penetration capability of the TSNCs was verified by tumor spheroids and 
tissue Immunol histochemistry. The antitumor efficacy and tumor metastasis were 
evaluated by tumor growth monitoring, tumor initial cells analysis, the histological 
analys is of triple-negative 4T1 breast tumor model. Moreover, the cardiotoxicity during 







































































2. Results and Discussion 
 
2.1. Synthesis and Characterization 
 
The copper sulfide nanodots (CuSNDs), DOX, and poly(lactic-co-glycolic acid (PLGA) were 
incorporated into the hydrophobic part of the F127 micelles using oil- in-water emulsion. 
Subsequently, the solvent was evaporated, and the emulsion was solidified to TSNCs. 
Transmission electron microscopy (TEM) analysis showed the TSNCs particle size is ca. 36 
nm (Figure 1A,B). The inset image of Figure 1A showed that the nanostructure was 
composed of several ultrasmall sized nanoparticles. They were well-dispersed in water, and 
the hydrodynamic diameter evaluated by dynamic light scattering was found to be ~40 nm 
(Figure S1A, Supporting Information), which is the preferable size for EPR effect for passive 
tumor targeting. The polydispersity index is 0.15. The UV-vis-NIR spectra (Figure 1C) of 
TSNCs displayed a characteristic strong absorption peak at 980 nm and a small absorption 
peak at 540 nm, corresponding for the component of CuSNDs and DOX in the TSNCs, 
respectively. Exposure of the TSNCs solution (2 OD, 100 μg mL-1) under continuous-wave 
NIR laser (808-nm) irradiation resulted in the raised solution temperature ranging from 20.1 
to 87.8 °C with various power densities within a few minutes (Figure 1D). From the 
temperature change curves, the obvious heating effect was observed, which further validated 
that the efficacy of TSNCs as a photothermal coupling agent. Due to photothermal conversion, 
the NIR-induced heat destroyed the structure of TSNCs, leading to disassembly and release of 
the DOX and the ultrasmall sized CuSNDs (~5 nm). The size distribution dramatically 
decreased from tens of nanometers to a few nanometers (Figure 1E,F), and the hydrodynamic 
size and polydispersity index of the disassembled nanoparticles measure were around 6.9 nm 
and 0.08, respectively (Figure S1B, Supporting Information). There was no significant 
change of particle size between before and after laser treatment, when no CuSNDs in the 





































































of the TSNCs were attributed to the CuSNDs mediated photothermal effect. No particle 
aggregation was observed after 5 days of incubation in PBS solution at 37 °C, and the 
hydrodynamic sizes of the TSNCs measured by DLS showed there are almost no differences 
at 1 or 5 days (Figure S3, Supporting Information), indicating the excellent physiological 













Figure 1. Characterization of TSNCs. (A) TEM images and (B) particle size distribution of 
TSNCs, inset: high-resolution images of TSNCs; (C) UV-vis-NIR spectra of TSNCs and 
DOX; (D) Temperature change curve of TSNCs under 808-nm laser irradiation with different 
laser power; (E) TEM images and (F) particle size distribution of TSNCs after laser 
irradiation. 
 
2.2 Dose- and Time-Dependent Cytotoxicity and Antitumor Efficacy In Vitro 
The DOX loading efficiency of the TSNCs was determined to be as high as 25.1% (by 
weight). We next investigated the drug release kinetics to check whether DOX could be 





































































without NIR laser exposure, the accumulated released DOX was extremely low (< 4 %) over 
a period of 60 min (Figure S4, Supporting Information). However, when the TSNCs were 
irradiated by NIR laser, about 90% of DOX was quickly released from the TSNCs by the laser 
power of 2.0 W cm-2, suggesting NIR laser-triggered drug release as a result photothermal 
effect of CuSNDs from the TSNCs. Under the NIR laser irradiation, the temperature of the 
TSNCs can be elevated rapidly by the photothermal energy conversion of the CuSNDs. Thus, 
the constructed TSNCs was destroyed by the high temperature to promote DOX release from 















Figure 2. Cytotoxicity comparison of 4T1 cells incubation with DOX or TSNCs for 24 h (A), 
48 h (B), and 72 h (C), respectively; (D) NIR laser-triggered DOX release for chemotherapy 
and its influence on cell DNA damage evaluated by γ-H2AX foci; (E) Quantification of the 






































































DOX shows toxicity at the high concentration. We hypothesize the TSNCs have lower 
cytotoxicity owing to their lower DOX release characteristics than DOX. Therefore, dose- and 
time-dependent cytotoxicity of DOX and TSNCs were evaluated in 4T1 breast cancer cell by 
MTT assay (Figure 2A-C). The cytotoxicity of both DOX and TSNCs increased with the 
increase of the time and dose. TSNCs was obviously less toxic than free DOX, which 
demonstrated that only a limited part of DOX was released from TSNCs when there was no 
laser irradiation. We also evaluated the cell viability of the various treatment, including DOX, 
TSNCs, TSNCs+laser, CuSNDs, and CuSNDs+laser, with different concentrations at 24 h 
after treatments (Figure S5, Supporting Information). The TSNCs+laser treatment showed the 
lowest viability in all the treatment, demonstrating the best anticancer effect. 
Next, cell DNA damage of DOX, TSNCs, and TSNCs plus laser (TSNCs+Laser) was 
studied by confocal fluorescent microscopy. Figure 2D showed that TSNCs+Laser treatment 
resulted in significant DNA damage (γ-H2AX staining) than DOX and TSNCs treatment. 
Quantitative analysis (Figure 2E) indicated that around 10-fold or 3- fold higher red 
fluorescence (γ-H2AX staining) were detected in TSNCs+Laser treated 4T1 cancer cells than 
CuSNDs+Laser or TSNCs treated groups. These results provided clear evidence that TSNCs 
induce stronger cell damage effect of 4T1 cancer cells.  
To compare the cellular uptakes of the nanoparticles with or without laser treatment, 
CuSNDs and TSNCs labeled with the NIR fluorescence dye Cy5.5, were incubated with 4T1 
breast cancer cells. The strongest fluorescence signals from TSNCs+laser group were 
observed in the 4T1 cells compared to CuSNDs, CuSNDs+Laser, and TSNCs group, 







































































2.3 In Vitro Deep Tumor Penetration of DOX Induced by Laser Irradiation 
To find out whether the TSNCs+Laser might result in enhanced DOX penetration in tumor, 
we used the multicellular spheroids (MCSs) derived from 4T1 breast cancer cells as an in 
vitro model. The tumor spheroids were treated with free DOX, TSNCs, and TSNCs+Laser for 
24 h, and the penetration process was measured by using confocal microscopy. As shown in 
Figure 3A, TSNCs irradiated by laser caused that more DOX was penetrated into the 4T1 3D 
tumor spheroids than free DOX and TSNCs. Fluorescence intensities of DOX were similar in 
10 μm depths from the bottom of the tumor spheroids in DOX, TSNCs, and TSNCs+Laser 
groups. When the depths come to 50 μm and 100 μm, the DOX fluorescence intensities in 
TSNCs+Laser group were obviously higher than those in DOX and TSNCs groups, indicating 
their high tumor penetration capability. 
We further evaluated anticancer efficacy against 4T1 cancer cells by MTT in vitro. As 
expected (Figure 3B), no obvious inhibition was observed over the no-treatment control, laser 
treatment, and CuSNDs groups, while TSNCs, free DOX, and CuSNDs with laser treatment 
(CuSNDs+Laser), showed limit cytotoxicity to the 4T1 cells. Obviously, TSNCs with laser 
treatment (TSNCs+Laser) showed best anticancer effect. About 30% or 55% of cells were 
killed by TSNCs or free DOX due to its anticancer effect, respectively, and about 69% of 
cells were killed in the CuSND+Laser group owing to the photothermal effect. When the cells 
were treated by TSNCs+Laser, more than 80% of cells were killed, which indicated the 
chemo- and photothermal synergistic therapy. These results collectively confirmed that the 






























































































Figure 3. (A) Deep penetration of DOX/TSNCs in 4T1 3D tumor spheroids. Z-stack images 
using confocal microscopy of DOX penetration into 3D 4T1 tumor spheroids treated with free 
DOX or TSNCs (with or without NIR laser). Scale bar was 200 μm.; (B) Cell viability of 4T1 
breast cancer cells treated with PBS (control), laser only, CuSNDs, TSNCs, DOX, CuSNDs 
plus laser (CuSNDs+Laser), and TSNCs+Laser, respectively. After incubation of PBS 
(control), CuSNDs, DOX, TSNCs, then the cells in CuSNDs and TSNCs groups were 





































































2.4. In Vivo Photoacoustic Imaging, Radiolabeling, Pharmacokinetics, Biodistribution, 
and, Fluorescence Imaging 
Photoacoustic imaging is an emerging imaging modality combining the advantages of high 
contrast optical imaging with ultrasound imaging in deep tissues.[38,39] Since the TSNCs have 
a high absorbance in the NIR region, photoacoustic imaging was used to monitor their 
accumulation in tumors at different time intervals. We next investigated the feasibility of 
using TSNCs for in vivo tumor photoacoustic imaging. Figure 4A shows representative 
photoacoustic images of a mouse with a 4T1 breast tumor, which are acquired at 1, 6, and 24 
h after intravenous administration of TSNCs. As expected, TSNCs initially accumulated in 
the tumor tissue, allowing tumor visualization at 1 h after i.v. injection. Then, the 
photoacoustic intensity increased at 6 h and reached a higher level at 24 h post- injection. 
These results demonstrated that the constructed TSNCs showed substantial tumor homing 
ability, probably due to the EPR effect. In vivo photoacoustic imaging of CuSNDs in breast 
orthotopic 4T1 tumor at different times after intravenous injection was also investigated. The 
contrast in the tumor (Figure S7, Supporting Information) was much weaker than TSNCs 
(Figure 4A), and no obvious enhancement was found after the time increased. 
The radiolabeling technique was used extensively to assess the in vivo characteristics of 
nanoparticles due to its high sensitivity.[40-42] We labeled TSNCs with radioisotope 64Cu to 
investigate the pharmacokinetics, and biodistribution in vivo. The pharmacokinetic profile of 
the 64Cu-labeled TSNCs ([64Cu]TSNCs) was measured by gamma counter to evaluate their 
time dependent blood concentrations. As shown in Figure 4B, the blood circulation of the 
TSNCs well conforms the two-compartment model. After the first distribution phase (rapid 
decline, half- life: 0.25 ± 0.12 h), the TSNCs had a long second elimination phase in 
circulating blood with a half- life of 7.20 ± 0.35 h, which is considered as the major process 
for TSNCs clearance. Nanoparticles with suitable modification such as poly(ethylene glycol) 





































































PLGA was used during the synthesis. The introducing of PLGA may plan an important role to 
enhance the circulation time of TSNCs in vivo. The long circulation of the TSNCs detains the 
macrophage clearance in the mononuclear phagocytic system (MPS), which may facilitate the 





















Figure 4. In vivo behaviors of TSNCs in breast orthotopic 4T1 tumor after intravenous 





































































(yellow dashed circle) was selectively enhanced; (B) Pharmacokinetics of TSNCs in mice 
from 0 to 24 h after intravenous injection  (n = 5); (C) Biodistribution of TSNCs 24 h post-
injection (n = 5); Fluorescence imaging of DOX/TSNCs in 4T1 tumor beard mice (D) and the 
dissected tumors (E) by IVIS imaging (n=3); Quantification of the mean fluorescent intensity 
of DOX/TSNCs in 4T1 tumor beard mice (F) and the dissected tumors (G). 
We also investigated the biodistribution of radiolabeled [64Cu]TSNCs. Quantitative 
biodistribution analysis (Figure 4C) showed high tumor uptake of the TSNCs (8.02 %ID g-1) 
at 24 h after i.v. injection, which was two-fold higher than CuSNDs (Figure S8, tumor uptake: 
3.27 %ID g-1). Notably, the efficient tumor uptake of the TSNCs should be attributed to their 
long circulation time in the blood (Figure 4B). The high level of liver uptake of the TSNCs is 
possibly owing to MPS absorption, whereas the uptake in the kidney can be possibly 
correlated with renal excretion.  
Mice bearing 4T1 tumors were administered intravenously with DOX or TSNCs. In vivo 
imaging system (IVIS) optical imaging was carried out at 24 h after i.v. injection to observe 
the accumulation of DOX in the tumors. A significantly enhanced DOX fluorescence signal 
was detected in the tumors in vivo and ex vivo of 4T1 tumors bearing mice treated with 
TSNCs than with DOX (Figure 4D,E). The quantitative analysis (Figure 4F,G) of the 
fluorescent intensity in TSNCs accumulated tumors at 24 h was significantly higher than in 
the DOX accumulated tumor (p < 0.05). Ex vivo dissected tumor fluorescence imaging and 
quantitative analysis at 24 h showed the similar results. Ex vivo images (Figure 5A) showed 
low accumulation in major organs, including heart, liver, spleen, kidney, and spleen. 
Importantly, we found that the DOX accumulation in the heart of the TSNCs treated mice was 
much lower than the DOX-treated mice. The staining (DAPI) tissue slices (Figure 5B) and 
quantitative fluorescent signal analysis (Figure 5C) demonstrated low amounts of DOX in 





































































data indicate possible lower cardiotoxicity of TSNCs. These results were consistent with the 
quantitative analysis of biodistribution. 
 
 
Figure 5. (A) Fluorescence imaging of major organs, including heart, liver, spleen, kidney, 
and lung after i.v. injection of DOX or TSNCs. (B) The tissues slices stained with DAPI 
(blue) showed DOX distribution in different major organs. (C) Quantification of the mean 
fluorescent intensity of DOX/TSNCs in major organs. 
 
2.5. In Vivo Deep Tumor Penetration of DOX Induced by Laser Irradiation 
Following the promising in tumor spheroids findings, the deep tumor penetration effects of 





































































slices were stained with anti-CD34 and anti-HIF-1α antibody to identify tumor blood vessels 
and tumor hypoxia areas. In the immunofluorescence staining study (Figure 6A), for 
TSNCs+Laser treatment, the green DOX fluorescence showed higher DOX fluorescence 
intensity in tumor sites, indicating strong uniform perfusion in the tumor interstitium. 
However, the DOX only or TSNCs with laser irradiation displayed weak signal in the tumors. 
The low signal of DOX was attributed to the low tumor uptake of the DOX, whereas, the 
weak signal of TSNCs in the tumor tissue was because of their large particle size. This 
suggests that TSNCs+Laser treatment can release DOX at tumor sites and the released DOX 
enables efficient extravasation and penetration into deep tumor space, whereas the penetration 
depth of DOX only or TSNCs without laser irradiation was limited. Moreover, the 
fluorescence intensity of DOX significantly increased in farther distance from the CD34-
identified tumor blood vessels and in HIF-1α- identified tumor hypoxia areas when tumors 
treated with TSNCs subjected to additional laser irradiation (Figure 6B). These results 
confirmed that the TSNCs+Laser had better ability to deliver the drug to the deeper tumor 
penetration depth. Therefore, much more cancer cells could be killed by the higher drug 





































































































Figure 6. (A) DOX penetration into the vascular sparing region of tumors intravenously 
injected with free DOX or TSNCs (with or without NIR laser) using confocal microscopy; (B) 
DOX penetration into the Hypoxic region of tumors intravenously injected with free DOX or 






































































2.6. In Vivo Antitumor Efficacy  
Due to the excellently enhanced tumor accumulation of TSNCs and deep tumor penetration 
with laser irradiation, we rationally evaluated the antitumor efficacy in vivo in 4T1 tumors 
bearing mice. Tumor surface temperature monitored by using a thermal camera increased 
rapidly to about 50 °C in CuSNDs+Laser and TSNCs+Laser groups subjected to laser 
treatment while tumor surface temperature of laser group reached 40 °C (Figure 7A,B). 
Before the tumor growth delay study, the alterations of cell apoptosis, cell proliferation, and 
cell thermal response in tumors were firstly identified by Hematoxylin and Eosin (H&E), 
TUNEL, Ki-67, and HSP 70 staining assays (Figure 7C) shortly after a variety of treatments 
(4 h post-treatment). Owing to the poor tumor accumulation, the free DOX-induced limited 
apoptosis or proliferation inhibition of 4T1 cells in vivo was found compared with that of the 
control group. Similarly, a small quantity of apoptosis and proliferation inhibition of 4T1 cells 
were observed in TSNCs group due to the poor DOX release and penetration in tumors. 
Compared with other groups, the treatment of TSNCs+Laser led to significantly more 

































































































Figure 7. Short-term antitumor effect in vivo. (A) Infrared thermal of 4T1 tumor bearing mice 
i.v. injected with saline, CuSNDs, TSNCs irradiated with NIR laser. (B) Temperature 
elevation at the tumor site after NIR laser radiation. (C) Representative H&E, TUNEL, Ki-67, 
and HSP 70 staining of Tumor sections 4 h after various treatments. 
In vivo tumor growth delay study was carried out on the 4T1 ortho topic tumor model. Due 
to the EPR effect, the tumor volumes of TSNCs group mice were a little less than those of 
DOX group mice (Figure S9, Supporting Information)., but the antitumor efficacy was not 
satisfactory resulting from the poor penetration of the drug in the tumor (Figure 8A). 





































































CuSNDs, DOX, and TSNCs group. As expected, TSNCs combined with laser irradiation with 
passive tumor targeting efficiency and deep penetration of DOX in tumor inhibited the tumor 
growth more effectively than other treatments. By the end of the treatment procedure, the 
tumor-bearing mice were sacrificed, and the resected tumors were photographed and weighed. 
The average tumor weight of TSNCs+Laser group significantly reduced by 95.9% in 
comparison to the respective control group, suggesting the novel strategy was the most 















Figure 8. Antitumor effect in vivo. (A) Tumor growth curves of mice bearing 4T1 tumors 
followed by various therapeutic methods; (B) Representative photograph of dissected tumors; 



















































































Figure 9. Anti-metastasis and tumor load-related response efficacy. (A) Representative 
photograph of pathological lung sections stained with H&E from each group of mice; (B) 
Representative photograph of liver pathological sections stained with H&E. 
 
2.7. Pulmonary and Hepatic Metastasis Evaluation 
Lethal pulmonary and hepatic metastasis is the main causes of mortality in breast cancer 
patients.[43,44] In our study, we observed a large number of lung metastatic lesions in mice in 
the control, laser, CuSNDs, TSNCs, and DOX groups on day 17 (Figure 9A). Fewer 
metastatic lesions were observed in groups of mice treated with CuSNDs+Laser, indicating 
those treatments were not capable to prevent tumor spread. However, no visible lung 
metastatic lesion was observed for the mice treated with TSNCs+Laser. Quantitative analysis 
shows that the number of metastatic lung nodules was obviously reduced after TSNCs+Laser 
treatment. Hepatic micrometastases were also found in the livers of the mice in the control, 
laser, CuSNDs, TSNCs, DOX, and CuSNDs+Laser treatment groups. However, the hepatic 
micro-metastases were significantly reduced in the TSNCs+Laser-treated group. Hence, 























































































Figure 10. (A) Representative images of 4T1 primary tumorsphere size seven days after 
various treatments; (B) 4T1 primary tumorsphere formation seven days after various 
treatments, grown at a density of 6000 cells/well. ***p < 0.001. 
2.8. Eliminates cancer stem cells (CSCs). 
Breast CSCs are believed to the major reason of disseminated tumor metastases. [45-47] We, 
therefore, determined whether TSNCs+Laser treatment could modulate CSCs populations in 
TNBC using tumorsphere assay. As shown in Figure 10, tumors treated with TSNCs+Laser 





































































a significant difference of tumorsphere number of the TSNCs+Laser group, compared with 
other treatment groups (Figure 10, ***p < 0.001). These data suggest that TSNCs+Laser 
treatment enhance the killing effect against CSCs. The treatment efficiently eradicated breast 
CSCs and inhibited the lung and liver metastasis. TSNCs are promising candidates for cancer 
therapy. The development of lung metastasis is eventually happened for most breast ca ncer 
patients after treatment and accounts for about 60% - 70% of death, which is possibly caused 
by CSCs due to their resistance to therapy. In our studies, DOX and CuSNDs moderately 
reduced the lung metastasis, and more importantly TSNCs+Laser treatment significantly 
reduced lung and liver metastasis in the murine 4T1 model. This is highly associated with the 
enhanced anti-CSC effect with TSNCs+Laser treatment, since the nanoparticles have long 
retention and deep penetration of the tumors. Moreover, the laser induced thermal- therapy 
also contributed to the CSCs killing. Therefore, the reduced metastasis of the mice in 
TSNCs+laser group could be attribute to the high-efficient CSCs killing effects and/or the 
reduced tumor burden by the combined therapeutic effects. 
 
2.9. In Vivo Cardiotoxicity Evaluation 
Despite DOX is an effective chemotherapeutic agent, cardiotoxicity is a major limiting factor 
in its use. Intravenously injection of TSNCs did not cause cardiotoxicity as evidenced by the 
echocardiography images. Figure 11 showed the comparison of the echocardiographic 
parameters at day 17 among the normal (control), DOX, and TSNCs+Laser groups. The 
animals in the DOX group had significantly reduced the ejection fraction (Figure 11A) and 
fractional shortening (Figure 11B) values on the day 17 when compared with the normal 
group. Also, the TSNCs+Laser group was found to similar parameters of cardiac function 
when compared to the DOX group. The representative images in each group are shown in 
Figure 11C. The left ventricles of the control and TSNCs+Laser treatment group were 





































































tissues, the DOX treated group showed a remarkable disorganization of cardiac muscle, 
edema and vacuolization of cells. However, there TSNCs+Laser group demonstrated the 
similar histological structures with no-treatment control group. This result demonstrates that 



















Figure 11. Changes in left ventricular function by control, DOX, or TSNCs+Laser treated 
mice. (A) Representative echocardiography images. (B) Percentage of ejection fraction (EF), 







































































2.10 Preliminary Toxicity (Blood Sample Analysis)  
There was no difference in body weight changes during the whole treatment progress as 
shown in Figure S10A (Supporting Information). Consistent with the therapeutic effect, 
TSNCs combined with laser irradiation brought about the least lung and liver metastasis. All 
treatments in 4T1 tumor-bearing mice didn’t influence the normal range of red blood cell 
(RBC), platelet (PLT), hemoglobin (HB), alanine aminotransferase (ALT), aspartate 
transaminase (AST), creatinine (CREA), blood urea nitrogen (BUN) and the physiological 
morphology analyzed by H&E stain (Figure S10B-S10H, Supporting Information). The 
preliminary investigations confirmed the TSNCs biosafety in vivo, indicating that TSNCs are 
vehicles for delivering DOX to effectively inhibit tumor growth with minimal toxicity at the 
tested dose. However, more systematic studies, such as long-term toxicity and immune-




In summary, we have developed a novel tumor penetrating multifunctional nanosystem for the 
cancer combination therapy. The nanosystem has the following advantages over the 
previously reported nanostructure for cancer treatment. i) the nanosystem can significantly 
improve the drug penetration depth under NIR laser exposure due to their changeable particle 
size; ii) the nanosystem has neglect cardiotoxicity owing to their high tumor uptake; iii) the 
nanosystem can eradicate breast CSCs and reduced the tumor burden, and then could inhibit 
lung and liver metastasis of TNBC; i.v.) the nanosystem is non-toxic after intravenous 
administration. Such nanosystem with multiple therapeutic functions may have substantial 









































































4. Experimental Section  
Materials: All chemicals and reagents were used as received without any further 
purification. CuCl2·2H2O, Na2S, doxorubicin hydrochloride (DOX), F127 
((EO)97(PO)69(EO)97), and PLGA were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Trypsin-EDTA, dulbecco’s modified eagle’s medium (DMEM), and fetal bovine 
serum were obtained from Gibco-BRL (Burlington, ON, Canada).  
Cell Culture and Animal Models: Mouse breast carcinoma 4T1 cell was obtained from the 
Institute of Biochemistry and Cell Biology (Shanghai, China). Cells cultured in DMEM 
supplemented with 10% FBS and 1% antibiotics (100 U mL-1 penicillin and 100 μg mL-1 
streptomycin) at 37°C and under a humidified atmosphere containing 5% CO2. All animal 
experiments were approved by the Institutional Animal Care and Use Committee of Zhejiang 
University School of Medicine. Four- to six-weeks-old female BALB/c mice were used for 
the experiments. To establish orthotopic tumor model, 2 × 106 4T1 cells suspended in PBS 
were innoculated into the mammary fat pad of the mice. 
Penetration of DOX/TSNCs (with or without laser) into Three-Dimensional (3D) 
Multicellular Tumor Spheroid  :A density of 10,000 cells/well of 4T1 cells seeded onto 
microplates and incubated for 48 h. After incubation of 10 μg/mL DOX, TSNCs with 
equivalent DOX concentration, cells of TSNCs with laser were then irradiated to NIR laser 
(2.0 W cm-2, 3 min). After another 4 h incubation, the spheroids were washed with PBS three 
times carefully, and then DOX fluorescence was measured using Z-stack imaging from the 
bottom of the spheroids with 10 μm intervals by a confocal laser scanning imaging system 
(Nikon A1). 
In Vivo and Ex Vivo Tumor Penetration of DOX/TSNCs (with or without laser) : Tumor-
bearing (4T1) BALB/c mice were randomly divided into DOX, TSNCs and TSNCs+Laser 
groups (n = 3, each group) by the tumor size reached around 5-8 mm. 24 h after injected 
intravenously with DOX concentration of 5 mg kg-1 DOX or TSNCs, DOX and TSNCs 
groups of mice were photographed by IVIS Lumina LT Series III (Perkin Elmer). The two 
groups of mice were sacrificed after being observed, tumors and all major tissues, including 
heart, liver, spleen, lung, and kidney, were collected and photographed as well. The radiance 
of each photograph was analyzed by using Living Image 4.5 software (Perkin Elmer). 24 h 
after given TSNCs, the mice of TSNCs+Laser group were then exposed to 808-nm laser 





































































In Vivo Tumor and Tissue Distribution of DOX : Tumors and all major tissues of each 
group above were fixed by paraformaldehyde. The equilibrated in 30% sucrose for an 
additional 24 h. Sections of the tissues were cut at a thickness of 15 μm on a freezing 
microtome. The tumor sections were incubated overnight with primary antibodies (rabbit 
monoclonal antibody against CD34 and rabbit monoclonal antibody against HIF-1α) after 
permeabilized with Triton X-100 and blocked by 10% normal calf serum. After washes with 
PBS, the sections were incubated with secondary fluorescent antibodies (Alexa Fluor 594 
donkey anti-rabbit) for 1 h. The 4',6-diamidino-2-phenylindole (DAPI) was used to stain the 
nuclei of both tumor sections and major tissues sections.  
In Vivo Therapeutic Efficacy: When the average diameter of orthotopic 4T1 tumors 
reached about 5-8 mm, tumor-bearing female BALB /c mice were respectively randomly 
assigned to control, laser, CuSNDs, TSNCs, DOX, CuSNDs+Laser and TSNCs+Laser groups 
(n = 3, each group). Mice of control and laser groups were injected intravenously with saline. 
Mice of DOX were injected DOX intravenously at the dose of 5 mg kg-1. Mice of TSNCs and 
TSNCs+Laser groups were injected intravenously with TSNCs at the dose of 5 mg kg-1 
(equivalent DOX concentration). Mice of CuSNDs and CuSNDs+Laser groups were injected 
intravenously with corresponding nanoparticles. 24 h later, the tumors in mice from the laser, 
CuSNDs+Laser, and TSNCs+Laser groups were irradiated with an 808-nm NIR laser (2.0 W 
cm-2, 3 min) and the temperature of the tumor was monitored by using a thermal camera 
(FLIR, ThermaCAM, U.S.A.). The mice of all the 7 groups were sacrificed 4 h after laser 
treatment, tumors were removed and placed in 4% paraformaldehyde for 24 h, and then 
embedded in paraffin for analysis. Paraffin-embedded 5 μm tumor sections were cut, 
deparaffinized, rehydrated. For Ki-67 and HSP 70 stain, slides were incubated overnight with 
rabbit monoclonal antibody against Ki-67 and rabbit monoclonal antibody against HSP 70 at 
4 °C and treated with an appropriate secondary antibody for 1 h at room temperature. The 
DAB (3, 3′-diaminobenzidine tetrahydrochloride) liquid system was used to coloration. The 
TUNEL assay was performed to assess apoptosis by using the Apoptosis Detection Kit. After 
inactivated the endogenous peroxidase by 3% H2O2, slides were incubated with the reaction 
mixture in a 37 °C humidified chamber for 60 min and incubated with anti-FITC HRP 
conjugate at 37 °C for 30 min. After colored with DAB at room temperature for 10 min, the 
reaction was terminated by washing with distilled water. The sections were observed with an 
Olympus VS120 slide scanner. 
The tumor growth delay study was carried in both 4T1 tumor-bearing mice. When the 





































































laser, CuSNDs, TSNCs, DOX, CuSNDs+Laser and TSNCs+Laser. Mice of control and laser 
groups were injected intravenously with saline. Mice of DOX were injected DOX 
intravenously at the dose of 5 mg kg-1. Mice of TSNCs and TSNCs+Laser groups were 
injected intravenously with TSNCs at the dose of 5 mg kg-1 (equivalent DOX concentration). 
Mice of CuSNDs and CuSNDs+Laser groups were injected intravenously with corresponding 
CuSNDs. The tumors in mice from the laser, CuSNDs+Laser, and TSNCs+Laser groups were 
irradiated with an 808-nm NIR laser (2.0 W cm-1, 3 min) 24 h later and a thermal camera 
(FLIR, ThermaCAM) was used to monitor the temperature of the tumor. After treatments, the 
length and width of the tumors were measured with a digital caliper every 2-3 day, and the 
tumor volumes were calculated as volume (mm3) = length × width2 × 0.5. Body weight of the 
mice was also recorded at the time of tumor size measurement. The 4T1 tumor beard mice 
were sacrificed on day 17. The blood of the mice was collected for blood routine, alanine 
aminotransferase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN) and 
creatinine (CREA) examinations. The tumors were collected, weighed, and the major organs 
were harvested and used for H&E staining. The sections were obtained with an Olympus 
VS120 slide scanner.  
Supporting Information  
Supporting Information is available from the Wiley Online Library or from the author. 
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A novel tumor penetrating multifunctional nanosystem for triple negative breast cancer 
combination therapy under photoacoustic images guidance was developed.  The nanosystem 
possesses neglect cardiotoxicity, can improve the drug penetration depth, eradicate breast 
cancer stem cells, and inhibit lung and liver metastasis. 
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